Skip to main content
Fig. 5 | Journal of Ovarian Research

Fig. 5

From: Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics

Fig. 5

Effect of PARP1i drug combinations in Ovsaho ovarian cancer cells. Dose-response curve of cell viability based on cell number count for PARP1i AG-14361 + TVB-2640 (top left), PARP1i AG-14361 + Bortezomib (top right), PARP1i AG-14361 + proTAME (bottom left) and PARP1i AG-14361+ GC7 (top right) after 72 h. Inhibitor concentrations were combined in 1:1 ratio. DMSO was used as control vehicle. Data is representative of three independent experiments for treatment and error bars are the standard deviation of technical replicates for n = 9. Cell counts were measured using live-im- aging in an IncuCyte Zoom microscopic station (Methods). (BTZ) Bortezomib, (TVB) TVB-2640

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us